InMed Pharmaceuticals: Pipeline Refocus, Merger Ambitions, and the Capital Conundrum

InMed Pharmaceuticals stands at a critical inflection point after shutting down its only revenue-generating segment and pivoting entirely to preclinical and early-stage drug development. The company’s lead asset, INM-901—targeting Alzheimer’s disease—has shown encouraging preclinical results, but all future progress is subject to successful regulatory engagement, new financing, and the closing and integration of its announced merger with Mentari Therapeutics. With cash resources dwindling and Nasdaq compliance in jeopardy, InMed’s business model is now a high-wire act: the company must deliver scientific and corporate execution under severe capital constraints, or risk insolvency and delisting. [S1] [N1] [N3] [N4]

Winding Down Commercial Operations and Betting on the Pipeline

The most material recent development for InMed Pharmaceuticals is the wind-down of its BayMedica commercial segment, which was the company’s only source of recurring revenue. This leaves InMed with no ongoing commercial operations, forcing a strategic refocus on early-stage drug development. As of June 30, 2026, the company reported $5.16 million in cash and equivalents and a net loss of $12.56 million for the year, underscoring liquidity pressures. [S1]

Concurrently, InMed announced a merger with Mentari Therapeutics in May 2026, with Mentari securing $200 million in financing ahead of the deal. This triggered a dramatic, if likely speculative, surge in InMed’s share price, but the merger has not yet closed. [N1] [N3] [N4]

The company’s Nasdaq listing is at risk due to minimum bid price non-compliance, with a 180-day cure period initiated in March 2026. This introduces further uncertainty regarding InMed’s access to capital markets and investor confidence. [S1]

Drug Development Economics: High-Cost R&D, No Revenue, and Extreme Financing Needs

With BayMedica shuttered, InMed is a pure-play, early-stage drug developer. Its economics are now characterized by high fixed costs (R&D and regulatory) and negligible operating leverage until a candidate reaches late-stage clinical trials or commercialization—a multi-year, capital-intensive journey. The company’s reported net loss of $12.56 million for FY26 and a cash position of $5.16 million as of March 31, 2026, highlight the imbalance between cash burn and available resources. [S1]

InMed’s pipeline consists of preclinical and early clinical assets: INM-901 for Alzheimer’s (pre-IND meeting planned), INM-089 for dry AMD (preclinical), and INM-755 cream for Epidermolysis Bullosa (Phase 2 complete, seeking partnerships). None are near commercialization, so revenue generation is at least several years away, contingent on successful clinical progression and regulatory approval.

The merger with Mentari Therapeutics, if completed, could infuse much-needed capital and potentially broaden the addressable pipeline. However, integration costs, organizational complexity, and the risk of dilution or shifting priorities may offset the immediate financial benefit.

Without recurring revenue or late-stage assets, InMed’s business model is entirely dependent on external financing—via equity, non-dilutive grants, or partnership/licensing deals—to fund R&D milestones. Failure to secure timely funding could halt development and threaten corporate survival.

Positioning in a Crowded and Risk-Laden Neurodegeneration Landscape

InMed’s competitive differentiation rests on its proprietary small molecules targeting CB1 and CB2 receptors—key nodes in the endocannabinoid system implicated in neurodegenerative diseases. The ability of INM-901 to cross the blood-brain barrier and its demonstrated neuroinflammation reduction in advanced human organoid models offer mechanistic promise, but clinical validation is still lacking. [S1]

The neurodegeneration and Alzheimer’s drug landscape is highly competitive, with large pharmaceutical incumbents, mid-cap biotechs, and academic spin-outs all pursuing diverse modalities (antibodies, small molecules, gene therapies). Companies with established clinical data or validated biomarkers typically command a capital and partnership advantage.

While InMed’s proprietary manufacturing approaches (chemical synthesis, biosynthesis, IntegraSyn) could eventually support cost-effective production and flexible scaling, these advantages are only monetizable if the pipeline advances to commercialization or is out-licensed.

Switching costs and barriers to entry in this sector are high, but so are development hurdles. InMed’s small size, lack of near-term revenue, and dependence on external funding make it vulnerable to both scientific and commercial setbacks.

Merger-Driven Funding and Clinical Progress Unlock Near-Term Value

A favorable outcome for InMed would see the Mentari Therapeutics merger close on schedule, unlocking access to the $200 million financing and enabling uninterrupted advancement of INM-901 and other pipeline candidates. Successful completion of the pre-IND meeting with the FDA in Q3 2026, followed by positive feedback and initiation of a Phase 1 trial in 2027, would de-risk the lead asset and set the stage for potential partnership or licensing deals. [N1] [S1]

This scenario could be confirmed by: (1) formal merger closing and transparent allocation of new funds to R&D; (2) positive regulatory interactions (pre-IND meeting minutes, IND acceptance); (3) initiation and early safety readouts from the first-in-human trial; and (4) progress on strategic partnerships for INM-755 or other non-core assets.

If these milestones are achieved, InMed could regain investor confidence, improve its listing compliance, and potentially attract new institutional capital or non-dilutive funding.

Pipeline Advances Amid Ongoing Capital Constraints and Execution Risk

The most plausible scenario is a protracted period of survival-focused operations. InMed may close the merger with Mentari, but integration could be slow and capital deployment may be staged or subject to milestones. The company is likely to advance INM-901 through the pre-IND process, but the timeline for IND submission and Phase 1 trial initiation could slip if funding or regulatory feedback is less favorable than hoped.

Ongoing cash burn and minimal near-term revenue create persistent going-concern risk, and any clinical or regulatory delays could force further dilution or asset sales. Nasdaq listing compliance may be regained through corporate actions (reverse split, if approved) or improved market sentiment post-merger, but the risk of delisting remains until fundamentals are demonstrably improved.

This scenario would be confirmed by steady but unspectacular progress on clinical milestones, periodic small-scale financing, and continued cost containment, but without a transformative partnership or out-licensing deal.

Liquidity Exhaustion and Delisting Trigger a Strategic Crisis

In the adverse scenario, the merger with Mentari is delayed or fails to close, leaving InMed with insufficient funds to advance its pipeline. Continued operating losses and lack of new financing would force the company to halt or significantly downsize R&D programs, erode workforce and institutional knowledge, and potentially lose access to key intellectual property.

If Nasdaq delisting occurs, InMed’s access to public capital would be severely impaired, likely resulting in a distressed asset sale, fire-sale licensing, or outright insolvency. The company’s ability to attract new partners or investors would be further diminished by a shrinking cash runway and lack of clinical progress.

Evidence of this scenario would include public disclosures of failed financing rounds, missed regulatory or clinical milestones, workforce reductions beyond existing lean operations, and delisting notices becoming final.

Pivotal Markers for InMed’s Survival and Value Creation

Closure and terms of the Mentari Therapeutics merger—including timing, access to the $200 million in financing, and integration plans.

Pre-IND meeting outcome for INM-901: documentation of FDA feedback, clarity on clinical trial design, and feasibility of IND submission in 2027.

Nasdaq listing status: progress toward regaining minimum bid price compliance, whether by market performance or corporate actions.

Cash burn rate and quarterly liquidity updates: actual versus projected runway, and any new equity or non-dilutive funding secured.

Initiation and early data from the INM-901 Phase 1 clinical trial, if disclosed, would be a major inflection point.

Updates on partnership or out-licensing discussions for INM-755 or other non-core assets, which could provide non-dilutive capital.

Management’s ability to retain talent and institutional knowledge following the commercial wind-down and through merger integration.

Any regulatory developments or external clinical data in the CB1/CB2 neurodegeneration space that could reframe competitive positioning.

Disclaimer: This is research-only, informational analysis and not investment advice. It may include AI-generated interpretation and general industry context. Always verify important details using primary sources.